Is Elafibranor a prescription drug? Can it be purchased and used by yourself?

Elafibranor is a drug in the clinical development stage. It is mainly used to treat metabolism-related diseases such as non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Developed by the French company Genfit, the drug is a selective PPAR α/δ dual agonist and has the potential to regulate lipid metabolism, reduce inflammatory responses and improve liver insulin sensitivity. Ilafibratenol has not yet been officially approved for marketing in China, so it is not a prescription drug in the conventional sense, and patients usually cannot obtain it directly in domestic medical institutions.

Since irafibratenol is still in the international drug regulatory approval process, its current use worldwide mainly depends on clinical trials or special medication channels. In some parts of Europe and the United States, the drug may be used by specific patients as "compassionate use" or "clinical trial use", but such use usually needs to be under the guidance of a doctor and supervised by compliance agencies. Therefore, even if a patient obtains irafibratenol through overseas channels, it should be used after evaluation by a professional doctor and cannot be regarded as an ordinary drug that can be purchased at will and taken by oneself.

From the perspective of drug safety, although irafibratenol has shown good tolerability and potential efficacy in early clinical studies, the risk-to-benefit ratio of its long-term use has not been fully verified, and self-use may bring unpredictable side effects. For example, PPAR agonist drugs may affect the cardiovascular system, renal function and lipid balance in the body. Failure to monitor these indicators when taking drugs by yourself may lead to adverse consequences. Therefore, patients must not obtain and use this medicine through the Internet or other informal channels.

In short, elafibratenol is not currently a prescription drug approved in China, and since it is not officially on the market, patients are not recommended to purchase and use it on their own. If patients suffer from diseases such as NASH or PBC, they should first consult a professional hepatology department or gastroenterologist and choose a formal treatment plan supported by evidence based on the condition. At the same time, if you are interested in participating in clinical research related to irafibratenol or obtaining medication information, you can obtain formal guidance through the hospital clinical trial platform or the international drug assistance channel. Purchasing and using such investigational drugs without a doctor's permission or supervision involves high risks and legal issues.

Reference materials:https://www.drugs.com/donanemab.html